Singapore, Oct. 14 -- US-based Waters Corporation hasunveiled theWaters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

With the rapid growth of cell and gene therapies, mRNA, and complex protein therapeutics, scientists face significant challenges in analyzing increasingly large and heterogeneous drug modalities - yet existing tools are limited in resolution, sensitivity, and compliance-readiness.

The Xevo CDMS System addresses these gaps with direct, individual-particle mass measurement for molecules up to 150+MDa, enabling previously unattainable analysis of protein com...